Testosterone undecanoate oral - TesoRx

Drug Profile

Testosterone undecanoate oral - TesoRx

Alternative Names: Low-T therapy - TesoRx; Oral TRT therapy - TesoRx; Testosterone replacement therapy - TesoRx; THG 1001; TSX-011

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TesoRx
  • Developer ASKA Pharmaceutical; TesoRx
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Hypogonadism

Most Recent Events

  • 01 Dec 2017 TesoRx and ASKA expand collaboration to develop and commercialise Testosterone undecanoate to South-East Asia for hypogonadism
  • 07 Nov 2017 TesoRx Pharma plans a phase I/IIa trial in Hypogonadism in USA (NCT03335254)
  • 06 Nov 2017 Phase-I/II clinical trials in Hypogonadism (In adults, In the elderly) in Japan (PO) (NCT03335254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top